Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Amsacrine combined with etoposide and methylprednisolone is a feasible and safe component in first-line intensified treatment of pediatric patients with high-risk acute lymphoblastic leukemia in CoALL08-09 trial.
Mezger K, Ebert S, Muhle HE, Stadt UZ, Borkhardt A, Dilloo D, Faber J, Feuchtinger T, Imschweiler T, Jorch N, Pekrun A, Schmid I, Schramm F, Zimmermann M, Horstmann MA, Escherich G. Mezger K, et al. Among authors: horstmann ma. Pediatr Blood Cancer. 2022 Dec;69(12):e29997. doi: 10.1002/pbc.29997. Epub 2022 Sep 21. Pediatr Blood Cancer. 2022. PMID: 36129234
The long-term impact of in vitro drug sensitivity on risk stratification and treatment outcome in acute lymphoblastic leukemia of childhood (CoALL 06-97).
Escherich G, Tröger A, Göbel U, Graubner U, Pekrun A, Jorch N, Kaspers G, Zimmermann M, zur Stadt U, Kazemier K, Pieters R, Den Boer ML, Horstmann M, Janka GE; CoALL study group, Hamburg, Germany. Escherich G, et al. Haematologica. 2011 Jun;96(6):854-62. doi: 10.3324/haematol.2010.039735. Epub 2011 Feb 17. Haematologica. 2011. PMID: 21330320 Free PMC article.
Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.
van der Veer A, Waanders E, Pieters R, Willemse ME, Van Reijmersdal SV, Russell LJ, Harrison CJ, Evans WE, van der Velden VH, Hoogerbrugge PM, Van Leeuwen F, Escherich G, Horstmann MA, Mohammadi Khankahdani L, Rizopoulos D, De Groot-Kruseman HA, Sonneveld E, Kuiper RP, Den Boer ML. van der Veer A, et al. Among authors: horstmann ma. Blood. 2013 Oct 10;122(15):2622-9. doi: 10.1182/blood-2012-10-462358. Epub 2013 Aug 23. Blood. 2013. PMID: 23974192 Free PMC article.
Aberrant ZNF423 impedes B cell differentiation and is linked to adverse outcome of ETV6-RUNX1 negative B precursor acute lymphoblastic leukemia.
Harder L, Eschenburg G, Zech A, Kriebitzsch N, Otto B, Streichert T, Behlich AS, Dierck K, Klingler B, Hansen A, Stanulla M, Zimmermann M, Kremmer E, Stocking C, Horstmann MA. Harder L, et al. Among authors: horstmann ma. J Exp Med. 2013 Oct 21;210(11):2289-304. doi: 10.1084/jem.20130497. Epub 2013 Sep 30. J Exp Med. 2013. PMID: 24081948 Free PMC article.
Interference with pre-B-cell receptor signaling offers a therapeutic option for TCF3-rearranged childhood acute lymphoblastic leukemia.
van der Veer A, van der Velden VH, Willemse ME, Hoogeveen PG, Petricoin EF, Beverloo HB, Escherich G, Horstmann MA, Pieters R, den Boer ML. van der Veer A, et al. Among authors: horstmann ma. Blood Cancer J. 2014 Feb 14;4(2):e181. doi: 10.1038/bcj.2014.5. Blood Cancer J. 2014. PMID: 24531445 Free PMC article. No abstract available.
91 results